Skip to main content

Closed

BLRX: BioLineRx Ltd. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth-95.9% / yr

Operating margin-780.2%

ROIC-36.7%

Financially safe

Stretched

Debt / equity0.54×

Interest coverage-9.8×

Current ratio1.58×

BioLineRx Ltd.

BLRXNASDAQ Capital Market·USD·Closed

BioLineRx Ltd.

BLRXNASDAQ·USD·Closed

$2.82

+4.44%

$2.82

+$0.12 (4.44%)

52W Range

28thpctl

Volume

0.20×avg

Mkt Cap

12.27MUSD

P/E

-1.5TTM

Div Yield

–ann

52W Range

28thpctl

Volume

0.20×avg

Market Cap

12.27MUSD

P/E Ratio

-1.5TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings